Abstract
The causative role of amyloid β 1–42 (Aβ42) aggregation in the pathogenesis of Alzheimer’s disease (AD) has been under debate for over 25 years. Primarily, scientific efforts have focused on the dyshomeostasis between production and clearance of Aβ42. This imbalance may result from mutations either in genes for the substrate, i.e., amyloid precursor protein or in genes encoding presenilin, the enzyme of the reaction that generates Aβ42. Currently, it is supposed that soluble oligomers of amyloid beta (AβOs) and not fibrillar Aβ42 within neuritic plaques may be the toxic factors acting on a very early stage of AD, perhaps even initiating pathological cascade. For example, soluble AβOs isolated from AD patients’ brains reduced number of synapses, inhibited long-term potentiation, and enhanced long-term synaptic depression in brain regions responsible for memory in animal models of AD. Concentrations of AβOs in the cerebrospinal fluid (CSF) of AD patients are often reported higher than in non-demented controls, and show a negative correlation with mini-mental state examination scores. Furthermore, increased Aβ42/oligomer ratio in the CSF of AD/MCI patients indicated that the presence of soluble AβOs in CSF may be linked to lowering of natively measured monomeric Aβ42 by epitopes masking, and hence, concentrations of AβOs in the CSF are postulated to as useful AD biomarkers.
This is a preview of subscription content, access via your institution.
References
Alzheimer A (1907) Uber eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift fur Psychiatrie und psychisch-gerichtliche Medizin 64:146–148
Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology 42:631–639
Baker-Nigh A, Vahedi S, Davis EG et al (2015) Neuronal amyloid-β accumulation within cholinergic basal forebrain in ageing and Alzheimer’s disease. Brain 138:1722–1737. https://doi.org/10.1093/brain/awv024
Barghorn S, Nimmrich V, Striebinger A et al (2005) Globular amyloid beta-peptide oligomer—a homogenous and stable neuropathological protein in Alzheimer’s disease. J Neurochem 95:834–847
Beason-Held LL, Goh JO, An Y, Kraut MA, O’Brien RJ, Ferrucci L, Resnick SM (2013) Changes in brain function occur years before the onset of cognitive impairment. J Neurosci 33:18008–18014
Beraldo FH, Ostapchenko VG, Caetano FA et al (2016) Regulation of amyloid β oligomer binding to neurons and neurotoxicity by the prion protein-mGluR5 complex. J Biol Chem 291:21945–21955
Boehm J, Kang MG, Johnson RC, Esteban J, Huganir RL, Malinow R (2006) Synaptic incorporation of AMPA receptors during LTP is controlled by a PKC phosphorylation site on GluR1. Neuron 51:213–225. https://doi.org/10.1016/j.neuron.2006.06.013
Braak H, Braak E (1996) Evolution of the neuropathology of Alzheimer’s disease. Acta Neurol Scand Suppl 165:3–12
Brito-Moreira J, Lourenco MV, Oliveira MM et al (2017) Interaction of amyloid-β (Aβ) oligomers with neurexin 2α and neuroligin 1 mediates synapse damage and memory loss in mice. J Biol Chem 292:7327–7337. https://doi.org/10.1074/jbc.M116.761189
Bruggink KA, Jongbloed W, Biemans EA, Veerhuis R, Claassen JA, Kuiperij HB, Verbeek MM (2013) Amyloid-beta oligomer detection by ELISA in cerebrospinal fluid and brain tissue. Anal Biochem 433:112–120. https://doi.org/10.1016/j.ab.2012.09.014
Cairns NJ, Ikonomovic MD, Benzinger T (2009) Absence of Pittsburgh compound B detection of cerebral amyloid β in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol 66:1557–1562
Chen S, Yadav SP, Surewicz WK (2010) Interaction between human prion protein and amyloid-beta (Abeta) oligomers: role OF N-terminal residues. J Biol Chem 285:26377–26383
Chromy BA, Nowak RJ, Lambert MP et al (2003) Self-assembly of Abeta(1–42) into globular neurotoxins. Biochemistry 42:12749–12760. https://doi.org/10.1021/bi030029q
Costantini C, Rossi F, Formaggio E, Bernardoni R, Cecconi D, Della-Bianca V (2005) Characterization of the signalling pathway downstream p75 neurotrophin receptor involved in beta-amyloid peptide-dependent cell death. J Mol Neurosci 25:141–156
Da Rocha-Souto B, Scotton TC, Coma M et al (2011) Brain oligomeric β-amyloid but not total amyloid plaque burden correlates with neuronal loss and astrocyte inflammatory response in amyloid precursor protein/tau transgenic mice. J Neuropathol Exp Neurol 70:360–376. https://doi.org/10.1097/NEN.0b013e318217a118
De Felice FG, Lourenco MV, Ferreira ST (2014) How does brain insulin resistance develop in Alzheimer’s disease? Alzheimer’s Dement J Alzheimer’s Assoc 10:S26–S32. https://doi.org/10.1016/j.jalz.2013.12.004
de la Monte SM (2014) Type 3 diabetes is sporadic Alzheimers disease: mini-review. Eur Neuropsychopharmacol 24:1954–1960. https://doi.org/10.1016/j.euroneuro.2014.06.008
de Leon MJ, Golomb J, George AE et al (1993) The radiologic prediction of Alzheimer disease: the atrophic hippocampal formation. AJNR Am J Neuroradiol 14:897–906
Englund H, Sehlin D, Johansson AS et al (2007) Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. J Neurochem 103:334–345
Englund H, Degerman Gunnarsson M, Brundin RM, Hedlund M, Kilander L, Lannfelt L, Pettersson FE (2009) Oligomerization partially explains the lowering of Abeta42 in Alzheimer’s disease cerebrospinal fluid. Neurodegener Dis 6:139–147. https://doi.org/10.1159/000225376
Esparza TJ, Zhao H, Cirrito JR et al (2013) Amyloid-beta oligomerization in Alzheimer dementia versus highpathology controls. Ann Neurol 73:104–119
Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS et al (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59:512–519
Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G et al (2008) PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 29:1456–1465
Fukumoto H, Tokuda T, Kasai T et al (2010) High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J 24:2716–2726. https://doi.org/10.1096/fj.09-150359
Gao CM, Yam AY, Wang X et al (2010) Aβ40 oligomers identified as a potential biomarker for the diagnosis of Alzheimer’s disease. PLoS One 5:e15725. https://doi.org/10.1371/journal.pone.0015725
Gaspar RC, Villarreal SA, Bowles N, Hepler RW, Joyce JG, Shughrue PJ (2010) Oligomers of beta-amyloid are sequestered into and seed new plaques in the brains of an AD mouse model. Exp Neurol 223:394–400
GBD 2015 Disease and Injury Incidence and Prevalence Collaborators (2016) Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388:1545–1602. https://doi.org/10.1016/S0140-6736(16)31678-6
GBD 2015 Mortality and Causes of Death Collaborators (2016) (2016) Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388:1459–1544. https://doi.org/10.1016/S0140-6736(16)31012-1
Georganopoulou DG, Chang L, Nam JM, Thaxton CS, Mufson EJ, Klein WL, Mirkin CA (2005) Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer’s disease. Proc Natl Acad Sci USA 102:2273–2276. https://doi.org/10.1073/pnas.0409336102
Gilman S, Koller M, Black RS et al (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64:1553–1562
Glabe CG (2008) Structural classification of toxic amyloid oligomers. J Biol Chem 283:29639–29643
Gómez-Isla T, Hollister R, West H et al (1997) Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer’s disease. Ann Neurol 41:17–24
Haas LT, Salazar SV, Kostylev MA, Um JW, Kaufman AC, Strittmatter SM (2016) Metabotropic glutamate receptor 5 couples cellular prion protein to intracellular signalling in Alzheimer’s disease. Brain 139:526–546
Hardy J, Gwinn-Hardy K (1998) Genetic classification of primary neurodegenerative disease. Science 282:1075–1079
Herskovits AZ, Locascio JJ, Peskind ER, Li G, Hyman BT (2013) A Luminex assay detects amyloid beta oligomers in Alzheimer’s disease cerebrospinal fluid. PLoS One 8:e67898. https://doi.org/10.1371/journal.pone.0067898
Holmes C, Boche D, Wilkinson D et al (2008) Long-term effects of Aβ42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372:216–223
Hölttä M, Hansson O, Andreasson U (2013) Evaluating amyloid-β oligomers in cerebrospinal fluid as a biomarker for Alzheimer’s disease. PLoS One 8:e66381. https://doi.org/10.1371/journal.pone.0066381
Holtzman DM, Herz J, Bu G (2012) Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med 2:a006312. https://doi.org/10.1101/cshperspect.a006312
Hong S, Ostaszewski BL, Yang T et al (2014) Soluble Abeta oligomers are rapidly sequestered from brain ISF in vivo and bind GM1 ganglioside on cellular membranes. Neuron 82:308–319
Hsieh H, Boehm J, Sato C et al (2006) AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 52:831–843
https://clinicaltrials.gov/ct2/show/NCT02477800. Retrieved 9 October 2017
http://www.alz.org/facts/overview.asp. Retrieved 21 August 2017
http://www.who.int/mediacentre/factsheets/fs362/en/ WHO Dementia Fact sheet. Retrieved 4 September 2017
http://www.alzforum.org/therapeutics/aducanumab. Retrieved 9 October 2017
Jack CR, Knopman DS, Jagust WJ et al (2013) Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12:207–216
Joiner ML, Lise MF, Yuen EY et al (2010) Assembly of a beta2-adrenergic receptor-GluR1 signalling complex for localized cAMP signalling. EMBO J 29:482–495
Jongbloed W, Bruggink KA, Kester MI et al (2015) Amyloid-β oligomers relate to cognitive decline in Alzheimer’s disease. J Alzheimers Dis 45:35–43. https://doi.org/10.3233/JAD-142136
Kasai T, Tokuda T, Taylor M et al (2013) Correlation of Abeta oligomer levels in matched cerebrospinal fluid and serum samples. Neurosci Lett 551:17–22. https://doi.org/10.1016/j.neulet.2013.06.029
Kayed R, Lasagna-Reeves CA (2013) Molecular mechanisms of amyloid oligomers toxicity. J Alzheimers Dis 33(Suppl 1):S67–S78. https://doi.org/10.3233/JAD-2012-129001
Kayed R, Head E, Thompson JL et al (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science NY 300:486–489. https://doi.org/10.1126/science.1079469
Kerchner GA, Boxer AL (2010) Bapineuzumab. Expert Opin Biol Ther 10:1121–1130. https://doi.org/10.1517/14712598.2010.493872
Kim T, Vidal GS, Djurisic M et al (2013) Human LilrB2 is a β-amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimer’s model. Science 341:1399–1404. https://doi.org/10.1126/science.1242077
Klein WL, Krafft GA, Finch CE (2001) Targeting small Abeta oligomers: the solution to an Alzheimer’s disease conundrum? Trends Neurosci 24:219–224
Klunk WE, Engler H, Nordberg A et al (2004) Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol 55:306–319
Koffie RM, Meyer-Luehmann M, Hashimoto T et al (2009) Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci USA 106:4012–4017
Lacor PN, Buniel MC, Chang L et al (2004) Synaptic targeting by Alzheimer’s-related amyloid beta oligomers. J Neurosci 24:10191–10200
Lacor PN, Buniel MC, Furlow PW et al (2007) Aβ oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer’s disease. J Neurosci 27:796–807
Ladiwala AR, Litt J, Kane RS et al (2012) Conformational differences between two amyloid beta oligomers of similar size and dissimilar toxicity. J Biol Chem 287:24765–24773. https://doi.org/10.1074/jbc.M111.329763
Lambert MP, Barlow AK, Chromy BA et al (1998) Diffusible, nonfibrillar ligands derived from Abeta1–42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95:6448–6453
Lannfelt L, Möller C, Basun H et al (2014) Perspectives on future Alzheimer therapies: amyloid-β protofibrils—a new target for immunotherapy. Arch Neurol 69:198–207. https://doi.org/10.1001/archneurol.2011.1538
Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM (2009) Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457:1128–1132. https://doi.org/10.1038/nature07761
Lazzari C, Kipanyula MJ, Agostini M, Pozzan T, Fasolato C (2015) Aβ42 oligomers selectively disrupt neuronal calcium release. Neurobiol Aging 36:877–885. https://doi.org/10.1016/j.neurobiolaging.2014.10.020
Lemere CA (2013) Immunotherapy for Alzheimer’s disease: hoops and hurdles. Mol Neurodegener 8:36. https://doi.org/10.1186/1750-1326-8-36
Lewczuk P, Kornhuber J (2011) Neurochemical dementia diagnostics in Alzheimer’s disease: where are we now and where are we going? Expert Rev Proteom 8:447–458
Lewczuk P, Esselmann H, Meyer M et al (2003) The amyloid-b (Ab) peptide pattern in cerebrospinal fluid in Alzheimer’s disease: evidence of a novel carboxyterminally elongated Ab peptide. Rapid Commun Mass Spectrom 17:1291–1296
Lewczuk P, Matzen A, Blennow K et al (2017a) Cerebrospinal fluid Abeta42/40 corresponds better than Abeta42 to amyloid PET in Alzheimer’s disease. J Alzheimers Dis 55:813–822
Lewczuk P, Riederer P, O’Bryant S et al (2017) Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: an update of the consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World J Biol Psychiatry (in press)
Lewis J, Dickson DW, Lin WL et al (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293:1487–1491
Li F, Tsien JZ (2009) Memory and the NMDA receptors. N Engl J Med 361:302–303. https://doi.org/10.1056/NEJMcibr0902052
Li S, Jin M, Zhang D, Yang T, Koeglsperger T, Fu H, Selkoe DJ (2013a) Environmental novelty activates beta2-adrenergic signaling to prevent the impairment of hippocampal LTP by Abeta oligomers. Neuron 77:929–941. https://doi.org/10.1016/j.neuron.2012.12.040
Li Y, Liu Y, Wang Z, Jiang Y (2013b) Clinical trials of amyloid-based immunotherapy for Alzheimer’s disease: end of beginning or beginning of end? Expert Opin Biol Ther 13:1515–1522. https://doi.org/10.1517/14712598.2013.838555
Martins IC, Kuperstein I, Wilkinson H et al (2008) Lipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils that affect learning in mice. EMBO J 27:224–233
McIntyre CK, McGaugh JL, Williams CL (2012) Interacting brain systems modulate memory consolidation. Neurosci Biobehav Rev 36:1750–1762. https://doi.org/10.1016/j.neubiorev.2011.11.001
Miller EC, Teravskis PJ, Dummer BW, Zhao X, Huganir RL, Liao D (2014) Tau phosphorylation and tau mislocalization mediate soluble Aβ oligomer-induced AMPA glutamate receptor signaling deficits. Eur J Neurosci 39:1214–1224. https://doi.org/10.1111/ejn.12507
Montoliu-Gaya L, Villegas S (2016) Aβ-Immunotherapeutic strategies: a wide range of approaches for Alzheimer’s disease treatment. Expert Rev Mol Med 18:e13. https://doi.org/10.1017/erm.2016.11
Morris GP, Clark IA, Vissel B (2014) Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer’s disease. Acta Neuropathol Commun 2:135. https://doi.org/10.1186/s40478-014-0135-5
Nelson PT, Alafuzoff I, Bigio EH et al (2012) Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 71:362–381. https://doi.org/10.1097/NEN.0b013e31825018f7
Orgogozo JM, Gilman S, Dartigues JF et al (2003) Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 61:46–54
Petroff OA (2002) GABA and glutamate in the human brain. Neuroscientist 8:562–573. https://doi.org/10.1177/1073858402238515
Qian H, Matt L, Zhang M et al (2012) β2-Adrenergic receptor supports prolonged theta tetanus-induced LTP. J Neurophysiol 107:2703–2712. https://doi.org/10.1152/jn.00374.2011
Rasool S, Martinez-Coria H, Wu JW, LaFerla F, Glabe CG (2013) Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg-AD mice. J Neurochem 126:473–482. https://doi.org/10.1111/jnc.12305
Reitz C, Mayeux R (2014) Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol 88:640–651
Sancesario GM, Cencioni MT, Esposito Z et al (2012) The load of amyloid-beta oligomers is decreased in the cerebrospinal fluid of Alzheimer’s disease patients. J Alzheimers Dis 31:865–878. https://doi.org/10.3233/jad-2012-120211
Santos AN, Ewers M, Minthon L et al (2012) Amyloid-β oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer’s disease. J Alzheimers Dis 29:171–176. https://doi.org/10.3233/JAD-2012-111361
Savage MJ, Kalinina J, Wolfe A et al (2014) A sensitive abeta oligomer assay discriminates Alzheimer’s and aged control cerebrospinal fluid. J Neurosci 34:2884–2897. https://doi.org/10.1523/jneurosci.1675-13.2014
Schupf N, Tang MX, Fukuyama H et al (2008) Peripheral Abeta subspecies as risk biomarkers of Alzheimer’s disease. Proc Natl Acad Sci USA 105:14052–14057. https://doi.org/10.1073/pnas.0805902105
Sehlin D, Söllvander S, Paulie S et al (2010) Interference from heterophilic antibodies in amyloid-b oligomer ELISAs. J Alzheimers Dis 21:1295–1301
Selkoe DJ (2011) Resolving controversies on the path to Alzheimer’s therapeutics. Nat Med 17:1060–1065. https://doi.org/10.1038/nm.2460
Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med 8:595–608. https://doi.org/10.15252/emmm.201606210
Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT (2011) Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 1:a006189. https://doi.org/10.1101/cshperspect.a006189
Sevigny J, Chiao P, Bussière T (2016) The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature 537:50–56. https://doi.org/10.1038/nature19323
Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL (2007) Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptordependent signaling pathway. J Neurosci 27:2866–2875
Shankar GM, Li S, Mehta TH et al (2008) Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat Med 14:837–842
Siemers ER, Friedrich S, Dean RA et al (2010) Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol 33:67–73. https://doi.org/10.1097/WNF.0b013e3181cb577a
Sivanesan S, Tan A, Rajadas J (2013) Pathogenesis of Abeta oligomers in synaptic failure. Curr Alzheimer Res 10:316–323
Sondag C, Dhawan G, Combs CK (2009) Beta amyloid oligomers and fibrils stimulate differential activation of primary microglia. J Neuroinflammation 6:1. https://doi.org/10.1186/1742-2094-6-1
Spencer B, Masliah E (2014) Immunotherapy for Alzheimer’s disease: past, present and future. Front Aging Neurosci 6:114. https://doi.org/10.3389/fnagi.2014.00114
Spinney L (2014) Alzheimer’s disease: the forgetting gene. Nature 510:26–28
Stine WB, Jungbauer L, Yu C, LaDu MJ (2011) Preparing synthetic Abeta in different aggregation states. Methods Mol Biol 670:13–32
Townsend M, Mehta T, Selkoe DJ (2007) Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J Biol Chem 282:33305–33312
Um JW, Kaufman AC, Kostylev M et al (2013) Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer aβ oligomer bound to cellular prion protein. Neuron 79:887–902. https://doi.org/10.1016/j.neuron.2013.06.036
Valera E, Spencer B, Masliah E (2016) Immunotherapeutic approaches targeting amyloid-β, α-synuclein, and tau for the treatment of neurodegenerative disorders. Neurotherapeutics 13:179–189
Verma M, Vats A, Taneja V (2015) Toxic species in amyloid disorders: oligomers or mature fibrils. Ann Indian Acad Neurol 18:138–145. https://doi.org/10.4103/0972-2327.144284
Viola KL, Klein WL (2015) Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis. Acta Neuropathol 129:183–206. https://doi.org/10.1007/s00401-015-1386-3
Wang YJ, Zhou HD, Zhou XF (2010) Modified immunotherapies against Alzheimer’s disease: toward safer and effective amyloid-β clearance. J Alzheimers Dis 21:1065–1075
Wang-Dietrich L, Funke SA, Kuhbach K et al (2013) The amyloid-beta oligomer count in cerebrospinal fluid is a biomarker for Alzheimer’s disease. J Alzheimers Dis 34:985–994. https://doi.org/10.3233/jad-122047
Watt AD, Perez KA, Rembach A et al (2013) Oligomers, fact or artefact? SDS-PAGE induces dimerization of beta-amyloid in human brain samples. Acta Neuropathol 125:549–564. https://doi.org/10.1007/s00401-013-1083-z
Wirths O, Multhaup G, Czech C et al (2001) Intraneuronal Abeta accumulation precedes plaque formation in beta-amyloid precursor protein and presenilin-1 doubletransgenic mice. Neurosci Lett 306:116–120
Xia W, Yang T, Shankar G et al (2009) A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol 66:190–199. https://doi.org/10.1001/archneurol.2008.565
Yamamoto N, Matsubara E, Maeda S et al (2007) A ganglioside-induced toxic soluble Abeta assembly. Its enhanced formation from Abeta bearing the Arctic mutation. J Biol Chem 282:2646–2655
Yang T, Li S, Xu H, Walsh DM, Selkoe DJ (2017) Large soluble oligomers of amyloid β-protein from Alzheimer brain are far less neuroactive than the smaller oligomers to which they dissociate. J Neurosci 4(37):152–163. https://doi.org/10.1523/JNEUROSCI.1698-16.2016
You H, Tsutsui S, Hameed S et al (2012) Abeta neurotoxicity depends on interactions between copper ions, prion protein, and N-methyl-d-aspartate receptors. Proc Natl Acad Sci USA 109:1737–1742
Younan ND, Sarell CJ, Davies P, Brown DR, Viles JH (2013) The cellular prion protein traps Alzheimer’s Abeta in an oligomeric form and disassembles amyloid fibers. FASEB J 27:1847–1858. https://doi.org/10.1096/fj.12-222588
Zhang Y, Hong Y, Bounhar Y et al (2003) p75 neurotrophin receptor protects primary cultures of human neurons against extracellular amyloid beta peptide cytotoxicity. J Neurosci 23:7385–7394
Zhang Y, Kurup P, Xu J et al (2011) Reduced levels of the tyrosine phosphatase STEP block β amyloid-mediated GluA1/GluA2 receptor internalization. J Neurochem 119:664–672. https://doi.org/10.1111/j.1471-4159.2011.07450.x
Zhang J, Peng M, Jia J (2014) Plasma amyloid-beta oligomers and soluble tumor necrosis factor receptors as potential bio-markers of AD. Curr Alzheimer Res 11:325–331
Zhao D, Watson JB, Xie CW (2004) Amyloid beta prevents activation of calcium/calmodulin-dependent protein kinase II and AMPA receptor phosphorylation during hippocampal long-term potentiation. J Neurophysiol 92:2853–2858
Zhao WQ, Santini F, Breese R et al (2010) Inhibition of calcineurin-mediated endocytosis and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors prevents amyloid beta oligomer-induced synaptic disruption. J Biol Chem 285:7619–7632. https://doi.org/10.1074/jbc.M109.057182
Acknowledgements
This study was supported by grants for neurodegenerative diseases, Medical University of Białystok, Poland. BM has received consultation and/or lecture honoraria from Roche, Cormay and Biameditek. PL received research support from the Innovative Medicines Initiative Joint Undertaking under Grant Agreement No. 115372, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution, and he received consultation and lectures honoraria from Innogenetics/Fujirebio Europe, IBL International, AJ Roboscreen, and Roche.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Rights and permissions
About this article
Cite this article
Mroczko, B., Groblewska, M., Litman-Zawadzka, A. et al. Amyloid β oligomers (AβOs) in Alzheimer’s disease. J Neural Transm 125, 177–191 (2018). https://doi.org/10.1007/s00702-017-1820-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-017-1820-x
Keywords
- Amyloid-β oligomer
- Protein aggregation
- Biomarkers
- Cerebrospinal fluid
- Alzheimer’s disease
- Neurodegeneration